	US 12,448,588 B2
	Composition comprising biosurfactant and persicomycin (3-(3′hydroxy)hydroxy fatty acid)
Alexandra Trambitas, Alzenau (DE); Jochen Kleinen, Heinsberg (DE); Jakob Müller, Haltern am See (DE); Monica Desiree Van Logchem, PA Zevenbergen (NL); and David Voigtländer, Duesseldorf (DE)
Assigned to Evonik Operations GmbH, Essen (DE)
Appl. No. 18/873,976
Filed by Evonik Operations GmbH, Essen (DE)
PCT Filed Jun. 19, 2023, PCT No. PCT/EP2023/066371 § 371(c)(1), (2) Date Dec. 11, 2024, PCT Pub. No. WO2024/002738, PCT Pub. Date Jan. 4, 2024.
Claims priority of application No. 22181475 (EP), filed on Jun. 28, 2022.
Prior Publication US 2025/0163345 A1, May 22, 2025
Int. Cl. C11D 1/83 (2006.01); C11D 1/66 (2006.01); C11D 3/00 (2006.01); C11D 3/20 (2006.01); C11D 3/37 (2006.01); C11D 3/386 (2006.01)

CPC C11D 1/662 (2013.01) [C11D 1/83 (2013.01); C11D 3/0036 (2013.01); C11D 3/2093 (2013.01); C11D 3/3707 (2013.01); C11D 3/38627 (2013.01); C11D 2111/12 (2024.01)]

20 Claims

1. A composition, comprising:

A) at least one biosurfactant, and

B) at least one persicomycin which is a 3-(3′-hydroxy) hydroxy fatty acid or salt thereof,

wherein the biosurfactant is other than a persicomycin and is selected from the group consisting of rhamnolipids, glucolipids, and sophorolipids, and

wherein the composition has a sum of A) and B) in an amount of from 2.0 wt.-% to 60 wt.-%, wherein percentages by weight refer to the total composition, and

wherein a ratio of component B) to component A) is in a range of 1:2000 to 1:3.